Article, 2024

Mapping the Periostin splice isoforms in atopic dermatitis and an in vitro asthma model – A multi-platform analysis using mass spectrometry and RT-qPCR

Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, ISSN 1878-2434, 1570-9639, 1878-1454, Volume 1872, 5, Page 141031, 10.1016/j.bbapap.2024.141031

Contributors

Rusbjerg-Weberskov, Christian E [1] Hollensen, Anne Kruse 0000-0002-5461-6893 [1] Damgaard, Christian Kroun 0000-0003-4940-0868 [1] Løvendorf, Marianne Bengtson 0000-0002-7361-5845 [2] [3] Skov, Lone 0000-0002-4784-9680 [2] [3] Enghild, Jan Johannes 0000-0001-9292-9172 (Corresponding author) [1] Nielsen, Nadia Sukusu 0000-0002-7361-0614 [1]

Affiliations

  1. [1] Aarhus University
  2. [NORA names: AU Aarhus University; University; Denmark; Europe, EU; Nordic; OECD];
  3. [2] Copenhagen University Hospital
  4. [NORA names: Capital Region of Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];
  5. [3] University of Copenhagen
  6. [NORA names: KU University of Copenhagen; University; Denmark; Europe, EU; Nordic; OECD]

Abstract

Periostin is a matricellular protein known to be alternatively spliced to produce ten isoforms with a molecular weight of 78-91 kDa. Within the extracellular matrix, periostin attaches to cell surfaces to induce signaling via integrin-binding and actively participates in fibrillogenesis, orchestrating the arrangement of collagen in the extracellular environment. In atopic diseases such as atopic dermatitis (AD) and asthma, periostin is known to participate in driving the disease-causing type 2 inflammation. The periostin isoforms expressed in these diseases and the implication of the alternative splicing events are unknown. Here, we present two universal assays to map the expression of periostin isoforms at the mRNA (RT-qPCR) and protein (PRM-based mass spectrometry) levels. We use these assays to study the splicing profile of periostin in AD lesions as well as in in vitro models of AD and asthma. In these conditions, periostin displayed overexpression with isoforms 3 and 5 standing out as highly overexpressed. Notably, isoforms 9 and 10 exhibited a divergent pattern relative to the remaining isoforms. Isoforms 9 and 10 are often overlooked in periostin research and this paper presents the first evidence of their expression at the protein level. This underlines the necessity to include isoforms 9 and 10 in future research addressing periostin splice isoforms. The assays presented in this paper hold the potential to improve our insight into the splicing profile of periostin in tissues and diseases of interest. The application of these assays to AD lesions and in vitro models demonstrated their potential for identifying isoforms of particular significance, warranting a further in-depth investigation.

Keywords

AD lesions, RT-qPCR, alternative splicing events, analysis, applications, arrangement, arrangement of collagen, assay, asthma, asthma model, atopic dermatitis, atopic diseases, cell surface, cells, collagen, conditions, dermatitis, disease, divergent patterns, environment, events, evidence, expression, extracellular environment, extracellular matrix, fibrillogenesis, implications, in vitro model, in vitro model of AD, induced signals, integrin binding, investigation, isoform 3, isoforms, lesions, levels, mRNA, mass spectrometry, matricellular protein, matrix, model, model of AD, molecular weight, multi-platform, multi-platform analysis, overexpression, patterns, periostin, periostin isoforms, potential, protein, protein levels, research, signal, significance, spectrometry, spliced isoforms, splicing, splicing events, splicing profiles, surface, tissue, type 2 inflammation, universal assay, weight

Funders

  • Novo Nordisk Foundation
  • The Velux Foundations

Data Provider: Digital Science